Limited stage small cell carcinoma of the gastrointestinal tract: a clinicopathologic and prognostic analysis of 27 cases

Department of Gastroenterology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, China.
Rare tumors 02/2013; 5(1):e6. DOI: 10.4081/rt.2013.e6
Source: PubMed

ABSTRACT Small cell carcinoma of the gastrointestinal tract is a rare and aggressive neuroendocrine tumor. This study aims to analyze the clinical characteristics and potential prognostic factors for patients with limited stage small cell carcinoma of the gastrointestinal tract. The records of 27 patients with limited stage small cell carcinoma of the gastrointestinal tract, who all received surgery with lymphadenectomy, were retrieved and analyzed retrospectively. The median age of patients was 60 years old (range 38-79). The primary locations of tumor were the esophagus (74.1%) and stomach (14.8%). The rate of preoperative accurate diagnosis (16.7%) was low for small cell carcinoma of the esophagus and stomach. 40.7% of all the patients had regional lymph node metastases. Five patients underwent surgery alone, and the other 22 were treated with surgery + postoperative chemotherapy. All patients had disease progression or recurrence. The overall median survival time was 10 months and the 1-year survival rate was 37.0%. Patients who received postoperative chemotherapy had a median survival time of 12 months, which was superior to the 5-month survival of for those who only had surgery (P<0.0001). TNM stage (P=0.02) and postoperative chemotherapy (P<0.0001) were considered as two prognostic factors in uni-variate analysis. Postoperative chemotherapy was a significant independent prognostic factor in multivariate analysis (P=0.01). The prognosis for patients with limited stage small cell carcinoma of the gastrointestinal tract remains dismal, however, postoperative chemotherapy may have the potential to improve the outcome for these patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: Small cell lung cancer (SCLC) patients, who have achieved complete or partial response after chemotherapy, should be followed with prophylactic cranial irradiation (PCI). PCI for extrapulmonary small cell carcinoma (EPSCC) is not routinely recommended. The purpose of this review is to discuss all aspects of PCI in management of EPSCC. Scope: Until October 15, 2013, the PubMed database, the online abstracts of American Society of Oncology (ASCO) and ASCO Genitourinary (GU) Cancers meetings and clinical trials website were searched using the following search keywords: 'SCC or EPSCC of per organ side and prophylactic cranial radiotherapy. The screened abstracts and manuscripts language were limited to English. The papers which has included largest case series and data of case/cases about prophylactic cranial radiotherapy and/or published until in last 10 years were selected. Findings: Many single center experiences showed low incidence of brain metastasis in patients with esophageal SCC. Due to the low incidence of brain metastasis, PCI is not recommended for esophageal SCC. The cranial metastatic SCC of genitourinary, colorectal, small bowel and appendix is extremely rare. Therefore, PCI should not be recommended. The frequency of brain metastasis of prostate small cell carcinoma is much higher (%16-19) compared to other counterparts of EPSCC. PCI can be performed in selected cases of prostate SCC. High rates (41%) of brain metastasis develop in head and neck SCC. PCI should be considered for patients with head neck SCC. Conclusion: In literature, the brain metastasis incidence of EPSCC might vary between 1.7% up to 40%. In many patients with ESPCC, PCI should not be recommended. However, we have to keep in mind that primary head and neck and prostate SCC are exceptions due to high incidence of cranial metastasis; PCI should be recommended for these patients on individual basis.
    Current Medical Research and Opinion 03/2014; 30(7). DOI:10.1185/03007995.2014.904771 · 2.37 Impact Factor

Preview (2 Sources)

Available from